Nautilus Biotechnology, Inc.
NAUT- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001808805
No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Nautilus Biotechnology, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 83 | 86 | +3 |
| Shares | 57.5M | 56.4M | −1.06M (−1.8%) |
| Value | $154.7M | $119.7M | −$35.0M (−22.6%) |
New holders (11)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 43,030 | $91.0K | 0.01% |
| Prelude Capital Management, LLC | 17,344 | $37.0K | 0.00% |
| Bank of Montreal | 15,109 | $33.0K | 0.00% |
| Simplex Trading, LLC | 3,468 | $7.00K | 0.00% |
| FMR LLC | 985 | $2.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 1,168 | $2.00K | 0.00% |
| Group One Trading, L.P. | 555 | $1.00K | 0.00% |
| CWM, LLC | 320 | $1.00K | 0.00% |
| Parallel Advisors, LLC | 363 | $1.00K | 0.00% |
| Capital Advisors, Ltd. LLC | 186 | $0 | 0.00% |
| Ellevest, Inc. | 193 | $0 | 0.00% |
Sold out (8)
Institutions that held Nautilus Biotechnology, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Crown Advisors Management, Inc. | 250,000 | $672.0K |
| Millennium Management LLC | 112,784 | $303.0K |
| FNY Investment Advisers, LLC | 25,600 | $68.0K |
| Jane Street Group, LLC | 12,459 | $34.0K |
| HB Wealth Management, LLC | 12,000 | $32.0K |
| Marshall Wace, LLP | 11,500 | $30.0K |
| Penserra Capital Management LLC | 4,175 | $11.0K |
| Point72 Hong Kong Ltd | 906 | $2.00K |